Decreased Fibrinolysis in Behçet’s Disease

Tova Chajek; Eta Aronowski; G Izak

doi:10.1055/s-0038-1648103

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 1973; 29(03): 610-618
DOI: 10.1055/s-0038-1648103

Original Article

Schattauer GmbH

Decreased Fibrinolysis in Behçet’s Disease

Tova Chajek

¹Departments of Hematology and Medicine B, Hadassah University Hospital, Jerusalem, Israel

,

Eta Aronowski

¹Departments of Hematology and Medicine B, Hadassah University Hospital, Jerusalem, Israel

,

G Izak

¹Departments of Hematology and Medicine B, Hadassah University Hospital, Jerusalem, Israel

› Author Affiliations

Abstract

Summary

The coagulation and fibrinolytic systems have been investigated in nine patients suffering from Behçet’s disease. Six of these had thrombophlebitis.

The results of these studies revealed markedly elevated fibrinogen concentration and increased factor VIII activity as well as a pronounced decrease in the spontaneous fibrinolytic activity. This latter finding may have resulted from the presence of a potent antiplasmin activity and that of an inhibitor of the plasminogen activator detected in these patients’ sera.

It is suggested that decreased fibrinolysis aggravates the thrombotic episodes frequently encountered in Behçet’s disease; accordingly treatment with fibrinolytic agents was found to offer marked benefits.

Full Text

References

References
1 Alkjaersig N, Fletcher A. P, Sherry S. 1959; The mechanism of clot dissolution by plasmin. Journal of Clinical Investigation 38: 1086.
2 Bachman F, Duckert F, Koller F. 1958; Stewart-Prower factor assay and its clinical significance. Thrombosis et Diathesis Haemorrhagiea (Stuttgart) 02: 24.
3 Behçet H. 1937; Über rezidivierendes, apthose, durch ein Virus verursachte Geschwüre am Mund, am Auge und an den Genitalien. Dermatologische Wochenschrift 105: 1157.
4 Biggs R, Macfarlane R. G. 1962. Human Blood Coagulation and its Disorders. T. A. Davis Company, Philadelphia; 389.
5 Bol J, Dalgaard J. B, Scott D. 1958; Mucocutaneous - ocular syndrome with intestinal involvement : A clinical and pathological study of four fatal cases. American Journal of Medicine 25: 857.
6 Boolukos P. 1960; Phlebitiden und Thrombosen grober Körpervenen als Begleiterscheinungen der Behçet’schen Krankheit. Helvetica Medica Acta 27: 264.
7 Chajek T, Fainaru M. 1973; Behcet’s disease with superior vena cava occlusion associated with decreased fibrinolysis. British Medical Journal 01: 782.
8 Curth H. D. 1946; Behcet’s syndrome, abortive form ( ?) (recurrent aphthous oral lesions and recurrent genital ulcerations). Archives of Dermatology 54: 481.
9 Dowling G. B, Dudgeon G. A, Perkius E. S. 1961; Discussion on Behcet’s disease. Proceedings of Royal Society of Medicine 54: 101.
10 Enoch B. A, Khoo T. C. L, Castillo J. L.Olivares, Grainger R. G, Henry L. 1968; Major vascular complications in Behçet’s syndrome. Postgraduate Medical Journal 44: 453.
11 Fearnley G. R, Balmforth G, Fearnley E. 1957; Evidence of a diurnal fibrinolytic rhythm with a simple method of measuring natural fibrinolysis. Clinical Science 16: 645.
12 Haim S, Sherf K. 1969; Behçet’s disease : Presentation of 11 cases and evaluation of treatment. Israel Journal of Medical Sciences 02: 69.
13 Hardisty R. M, Macpherson J. C. 1962; One-stage factor VIII (anti haemophilic globulin) assay and its use on venous and capillary plasma. Thrombosis et Diathesis Haemor- rhagica (Stuttgart) 07: 215.
14 Hardisty R. M, Ingram G. I. C. 1965. Bleeding Disorders, Investigation and Management. T. A. Davis Company: Philadelphia; 307.
15 Izak G, Galewski K, Eyal Z. 1967; Studies on hypercoagulable state. Thrombosis et Diathesis Haemorrhagiea (Stuttgart) 18: 544.
16 Izak G, Galewski K. 1966; Studies on experimentally induced hypercoagulable state in rabbits. Thrombosis et Diathesis Haemorrhagiea 16: 228.
17 Katzenellenbogen I. 1950; Behçet’s syndrome. Archives of Dermatology 51: 418.
18 Koller F, Loeliger A, Duckert F. 1951; Experiments on a new clotting factor. Acta Haematologica 06: 1.
19 Lee R. I, White P. D. 1955; A clinical study of the coagulation time of blood. American Journal of Medical Science 145: 495.
20 Merskey C, Kleiner G. J, Johnson A. J. 1966; Quantitative estimation of split products of fibrinogen in human serum, relation to diagnosis and treatment. Blood 28: 1.
21 Nazzaro P. 1966. Cutaneous manifestation of Behçet’s disease. In: Monacelli M, Nazzaro P. S. (eds.), Symposium on Behçefs Disease. Rome, Karger, A. G: Basel, Switzerland; 15.
22 Nilsson I. M, Krook H, Sternby N. H, Söderberg E, Söderstrong N. 1961; Severe thrombotic disease in a young man with bone marrow and skeletal changes and with a high content of an inhibitor in the fibrinolytic system. Acta Medica Scandinavia 169: 323.
23 Quick A. T. 1951. The Physiology and Pathology of Haemostasis. Lea and Febiger: Philadelphia; 125.
24 Ratnoff O. D, Menzie C. 1951; A new method for the determination of fibrinogen in small samples of plasma. Journal of Laboratory and Clinical Medicine 37: 316.
25 Shanberge J. N, Matsuaka T, Fauktjj H. 1967; A simple method for the preparation of a substrate for a one stage factor. Technical Bulletin, Regional Medical Technology 37: 67.
26 Strachan R. W, Wigzell F. W. 1963; Polyarthritis in Behçet’s multiple symptom complex. Annals Rheumatic Diseases 22: 26.
27 Tomas E. W. P. 1947; So-called triple-symptom complex of Behçet. British Medical Journal 04: 14.
28 von Kaulla K. N. 1958; A new method : Method for evaluation of human fibrinolysis. American Journal of Clinical Pathology 29: 104.
29 Wolf S. M, Schotland D. L, Phillips L. L. 1965; Involvement of nervous system in Behçet’s syndrome. Archives of Neurology 12: 315.